Mechanism of Action

Imatinib functions by selectively inhibiting the BCR-ABL tyrosine kinase, an abnormal
enzyme produced by the Philadelphia chromosome mutation in CML. It also inhibits other
tyrosine kinases such as c-KIT and platelet-derived growth factor receptor (PDGFR),
which are implicated in various cancers. By blocking these enzymes, Imatinib prevents
phosphorylation of substrates involved in cell proliferation and survival, thereby inhibiting
tumor growth and inducing apoptosis in malignant cells.

Benefits and Advantages

Imatinib’s targeted mechanism allows it to effectively treat malignancies driven by specific
genetic mutations, reducing damage to normal cells compared to traditional chemotherapy.
Its oral administration facilitates outpatient treatment and improves patient quality of life.
Manufactured under GMP conditions, the Imatinib API meets high standards of purity and
consistency suitable for pharmaceutical formulation and compounding.

Side Effects and Risks

Common side effects associated with Imatinib include nausea, edema, muscle cramps,
rash, and fatigue. More serious but less frequent adverse events include hepatotoxicity,
cardiotoxicity, and myelosuppression. Regular monitoring of liver function and blood
counts is recommended during treatment to manage potential risks.

Conclusion

Imatinib remains a cornerstone in targeted cancer therapy due to its specificity and
efficacy against tyrosine kinase-driven malignancies. The availability of GMP-grade
Imatinib API supports the production of pharmaceutical formulations designed for clinical
use in oncology.